ArticleNature communications2022
DNA-based platform for efficient and precisely targeted bioorthogonal catalysis in living systems.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 98 citations in OpenAlex.
- COF@DNAzyme Empowering Endogenous Copper for One-Stitch Bioorthogonal Catalysis-Based Anticancer Therapy.Angewandte Chemie (International ed. in English) · 2026Article
- Programmable nanomedicine via bioorthogonal molecular engineering.Nano convergence · 2026Review
- A bioorthogonal-catalytic artificial antigen-presenting cell for chemo- and immuno-therapy.Chemical science · 2026Article
- Bioorthogonal Cyclization Reactions for the Synthesis of Cytotoxic Drugs in Cancer Treatment.ACS omega · 2025Review
- Exploring New Bioorthogonal Catalysts: Scaffold Diversity in Catalysis for Chemical Biology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Bio-orthogonal Glycan Imaging of Cultured Cells and Whole AnimalACS central science · 2025Article
- A DNA origami-based enzymatic cascade nanoreactor for chemodynamic cancer therapy and activation of antitumor immunity.Science advances · 2025Article
- Bioorthogonal Janus microparticles for photothermal and chemo-therapy.Smart medicine · 2024Article
- Modular Fabrication of Bioorthogonal Nanozymes for Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- Late-Stage Functionalization of Living Organisms: Rethinking Selectivity in Biology.Chemical reviews · 2024Review
- Polarization of macrophages to an anti-cancer phenotype throughChemical science · 2024Article
- Development of Essential Oil Delivery Systems by 'Click Chemistry' Methods: Possible Ways to Manage Duchenne Muscular Dystrophy.Materials (Basel, Switzerland) · 2023Review
- A narrative review: progress in transition metal-mediated bioorthogonal catalysis for the treatment of solid tumors.Translational cancer research · 2023Review
- Biofuels and Nanocatalysts: Python Boosting Visualization of Similarities.Materials (Basel, Switzerland) · 2023Article
- Article
- Designing Bioorthogonal Reactions for Biomedical Applications.Research (Washington, D.C.) · 2023Review
- A DNAzyme-augmented bioorthogonal catalysis system for synergistic cancer therapy.Chemical science · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As one of the typical bioorthogonal reactions, copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) reaction holds great potential in organic synthesis, bioconjugation, and surface functionalization. However, the toxicity of Cu(I), inefficient catalytic activity, and the lack of cell specific targeting of the existing catalysts hampered their practical applications in living systems. Herein, we design and construct a DNA-based platform as a biocompatible, highly efficient, and precisely targeted bioorthogonal nanocatalyst. The nanocatalyst presents excellent catalytic efficiency in vitro, which is one order of magnitude higher than the commonly used catalyst CuSO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.